Prof. Menno Prins receives grant for feasibility study start-up
The MBx research group at TU/e investigates novel biosensing technologies for which it has developed proofs-of-concept and filed patent applications. Based on these results, the group would like to found a company in 2017. The Take-off phase 1 grant of 40,000 euros received from NWO and ZonMw enables Prof. Menno Prins to develop a business roadmap for a start-up in Body Biomolecular Monitoring.
Partner in the study is Medifold, a company specialized in business development in the field of medical device technologies. The company has experience in bringing early technology concepts to the level of certified products, with a profitable customer base and a professional organization. TU/e and Medifold will jointly perform the feasibility study for founding a company in 2017.
Prof. Prins studied Applied Physics at Delft University of Technology (cum laude). He received a PhD from Radboud University Nijmegen in 1995. Thereafter he moved to Philips Research where he worked on microfluidics and point-of-care biosensing. Since 2005 he also worked as parttime professor at TU/e. Since 2014 prof. Prins is fulltime professor in the departments of BioMedical Engineering and Applied Physics, in the field of Molecular Biosensing for Medical Diagnostics (MBx). The research focuses on novel detection principles and novel molecular systems for particle-based in-vitro and in-vivo biosensing, aiming at biomolecular detection in complex environments with high sensitivity, specificity and biocompatibility. The activities are part of the Institute for Complex Molecular Systems (ICMS) and the Strategic Area Health (SA Health).